Sensei Biotherapeutics Inc SNSE.OQ SNSE.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Sensei Biotherapeutics Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 2.1% in the last three months.
Wall Street's median 12-month price target for Sensei Biotherapeutics Inc is $4.00, above its last closing price of $0.42.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.29 | -0.28 | -0.31 | Missed | -12 |
Sep. 30 2024 | -0.31 | -0.31 | -0.29 | Beat | 7.2 |
Jun. 30 2024 | -0.30 | -0.29 | -0.28 | Beat | 2.9 |
Mar. 31 2024 | -0.27 | -0.27 | -0.32 | Missed | -16.4 |
Dec. 31 2023 | -0.31 | -0.31 | -0.30 | Beat | 2.5 |
Sep. 30 2023 | -0.34 | -0.34 | -0.28 | Beat | 17.4 |
Jun. 30 2023 | -0.33 | -0.33 | -0.31 | Beat | 6.2 |
Mar. 31 2023 | -0.36 | -0.36 | -0.33 | Beat | 7.3 |
This summary was machine generated May 5 at 12:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)